Wednesday, 26 November 2014
Last updated 7 hours ago
Jul 31 2014 | 11:41am ET
Valeant Pharmaceuticals International turned its second-quarter results announcement into another pitch for its $54 billion offer for rival Allergan Inc.
The Canadian company, which is working with Pershing Square Capital Management on its bid for Allergan, pointed to growth in almost all of its business lines as it announced higher profits and sales. And it said that it remains “focused on completing the Allergan transaction,” in spite of that company’s opposition to it.
Valeant has launched a hostile tender offer for Allergan, while Pershing Square seeks to oust the company’s board. Valeant said it planned to integrate Allergan in much the same way it merged with Bausch & Lomb.
That’s not likely to offer much comfort to Allergan, which has blasted Valeant as a serial acquirer with an unsustainable business strategy.
Nov 4 2014 | 9:45am ET
Data management is important to every business, but for hedge funds, it is critical. FINalternatives recently asked Peter Sanchez, CEO of Northern Trust Hedge Fund Services, how fund managers can deal with the demands of managing data while at the same time remain transparent and abide by operational best practices. Read more…
Reg NMS created a huge bifurcation in equity markets and while much of what has followed has been positive, in terms of lower fees and greater liquidity, many traders would like to see the market come...